Quick Facts: Ульгастран

• Approved Indications: Treatment of mild-to-moderate forms of heart failure.
• Therapeutic Actions: Supports cardiac function.

---

Therapeutic Overview of Ульгастран

Ульгастран is authorized for the treatment of mild-to-moderate forms of heart failure. The therapeutic application involves providing support for cardiac function as part of a patient's established management strategy. Clinical evaluation of this medicine has shown an ability to contribute to the overall management of the condition, particularly in cases where symptoms are present with limitations on physical activity, but less severe than advanced disease. Benefits reported in clinical settings are primarily related to the supportive effect on the heart's pumping action, aiming to maintain patient stability in accordance with accepted clinical standards.

Who Can and Cannot Use Ульгастран (Sucralfate)?

Eligibility for Ульгастран is defined by official regulatory documentation and centers on patient demographics and organ function.

Contraindications and Restrictions

Classification	Population/Condition
Absolute Contraindication	Patients with known hypersensitivity reactions to Sucralfate or any of its excipients.
Use Not Established	Pediatric patients (children and adolescents). Safety and effectiveness data are lacking in this age group.
Restricted/Use with Caution	Patients with impaired renal function or chronic renal failure (including dialysis). This is due to the risk of aluminum accumulation.
Conditional Use	Older Adult/Geriatric patients, due to the higher frequency of decreased renal function, requiring cautious dosage selection.
Conditional Use	Pregnant or lactating women. Use is only advised if clearly needed, as adequate human studies are unavailable.

Standard labeled use is generally permitted for adult patients requiring short-term or maintenance therapy for duodenal ulcers. The official profile establishes restrictions primarily around kidney function and age groups with insufficient data, ensuring that individuals at high risk for toxic accumulation are managed with caution.

Interactions with other medicines and products

The official interaction profile of Ульгастран (Sucralfate) is defined by its non-systemic action, primarily causing pharmacokinetic interactions due to binding to concomitant agents in the gastrointestinal tract.

Exposure-Modifying Substances

Simultaneous administration can result in a reduced extent of absorption (bioavailability) for several specific oral medicines. Affected substances include the fluoroquinolone antibiotics (e.g., ciprofloxacin, norfloxacin, and ofloxacin), digoxin, the H2-receptor antagonists cimetidine and ranitidine, as well as ketoconazole, phenytoin, l-thyroxine, and theophylline. Due to the potential to alter absorption, Ульгастран should be administered separately from other oral drugs when alterations in bioavailability are considered critical.

Timing and Separation Requirements

To mitigate the absorption interaction, regulatory documents state that affected oral medications must be administered 2 hours before Ульгастран. Antacids, which represent an additive aluminum source, must not be taken within one-half hour before or after Ульгастран.

Additive Aluminum Risk

The pharmacodynamic interaction with aluminum-containing products (such as antacids) may increase the total body burden of aluminum. This risk is clinically significant for chronic renal failure and dialysis patients, as their impaired excretion of absorbed aluminum can lead to aluminum accumulation and toxicity.

The action of Ульгастран (Sucralfate) is defined by a local, non-systemic, dual mechanism that involves physical isolation of damaged cells and modulation of intrinsic cytoprotection pathways.

---

️ Localized Physical Shielding and Selective Binding

This domain covers the compound's initial pH-dependent activation and its highly selective physical interaction with mucosal damage. In the acidic environment of the stomach, Sucralfate polymerizes into a viscous, polyanionic gel that electrostatically adheres to positively charged proteins found exclusively at ulcer or erosion sites. This immediate adherence creates a physical barrier that isolates the damaged cells from the continuous chemical and lytic stress caused by gastric acid, pepsin, and bile salts.

---

Modulation of Intrinsic Cytoprotection Pathways

The compound engages pathways related to intrinsic repair and regeneration signaling. The physical barrier limits the degradation of endogenous growth factors (like EGF), maintaining their local availability. It also locally stimulates the synthesis of prostaglandins ( PGE2), amplifying the secretion of protective mucus and bicarbonate. These combined actions result in a local environment that supports accelerated epithelial cell proliferation and restoration of mucosal integrity.

---

Mechanism Constraints: Acid Dependency

The entire cascade is functionally constrained by the requirement for an acidic pH to initiate polymerization, meaning the primary mechanism is less effective if gastric acidity is suppressed by other medications. Furthermore, its strong binding property can lead to the adsorption of other orally administered substances in the digestive tract.

How to Use Ульгастран — Administration Guidelines

Administration of Ульгастран, containing the active ingredient Sucralfate, follows established protocols for proper usage.

---

Administration Scope

Instruction	Detail
Route of administration	Oral administration only, utilizing either the tablet or the liquid suspension form.
Dosing schedule	The established adult dose is 1 gram for both short-term active ulcer treatment and subsequent maintenance therapy.
Timing in relation to meals (if applicable)	The dose must be taken on an empty stomach to ensure proper action of the active ingredient.
Preparation requirements (if applicable)	The oral suspension requires shaking well immediately before measuring the dose.
Age-group administration rules	Dose selection for older adults should be cautious, typically initiating at the lower end of the established range.
Special procedural conditions	Antacids should not be taken within one-half hour before or after administration. Other Oral Medications must be administered separately (e.g., at least two hours before the dose) to prevent altered absorption.

---

Instruction Classifications (High-Level)

Classification	Detail
Administration method type	Oral
Frequency pattern	Multiple times daily (four times daily for acute use, twice daily for maintenance).
Use-context constraints	The frequency and duration are dependent on the clinical need: a higher, four-times-daily regimen for acute healing, and a twice-daily regimen for post-healing maintenance.

---

Connection to the Overall Use Protocol

The use of the medicine involves specific timing protocols that govern when and how the dose is administered relative to meals and other products. The established schedule defines two distinct frequency patterns and corresponding short-term (up to 8 weeks) or long-term durations. These administration constraints are utilized to ensure consistency in product usage.

Evidence for Use in Active Duodenal Ulcers

Ульгастран was studied for its use in conditions involving active ulcers in the duodenum. The primary research exploring this use involved short-term randomized controlled trials (RCTs) focusing on adult patients. Researchers examined outcomes linked to inflammatory or irritative states, mainly focusing on the measured rate of changes to the ulcer site, confirmed visually by endoscope. Research also monitored patient-reported outcomes describing perceived discomfort, such as changes in pain and antacid use.

The findings generally show patterns related to the measured outcomes in the short treatment windows, typically lasting 4 to 8 weeks. The evidence supporting the design of these studies is broadly categorized as well-established. Due to the short duration of these initial studies, long-term outcomes are not fully established.

---

Evidence for Preventing Ulcer Recurrence (Maintenance Studies)

Beyond the initial healing phase, Ульгастран was evaluated in intermediate to long-term maintenance trials, observing patients for up to 6 months to 1 year. Research explored patient groups who had achieved initial ulcer healing, and the main outcome research monitored was the ulcer recurrence rate. Studies describes data patterns related to the reappearance of ulcers.

---

Long-Term Follow-up and Research Gaps

Research has mostly concentrated on the acute treatment and subsequent prevention phases; thus, follow-up durations were often limited to one year. Long-term effects are not fully established because the evidence generally does not track patients beyond these controlled trials. Limited information for long-term outcomes means that the research landscape is lacking data on the time scale beyond the study period.

Ульгастран was also evaluated in patient populations beyond the general adult ulcer patient. One notable research scenario was observed in some studies that examined the use of the medicine in a research setting for managing risk factors related to stress ulcers in critically ill adult patients. Studies show that data for certain groups remain insufficient and that there is a lack of contemporary comparative trial evidence.

Common questions about Ульгастран (FAQ)

Q: What is the primary use of this medication (acetaminophen and caffeine)?

Official product information indicates that this combination medication is primarily used for the temporary relief of minor aches and pains. This includes pain associated with common conditions such as headache, muscular aches, the common cold, arthritis, toothache, and menstrual cramps.

Q: Does this medication contain aspirin or other NSAIDs?

This medication contains acetaminophen and caffeine as its active ingredients. Users are advised to carefully check the product label’s Drug Facts section. A product containing only acetaminophen and caffeine, such as this one, would not include an NSAID like aspirin.

Q: Can I take this medicine if I have a history of liver disease?

Regulatory warnings state that a doctor or health professional should be consulted before use if there is a history of liver disease or severe hepatic impairment. Acetaminophen use is associated with cases of acute liver failure, and the official label includes a warning about potential severe liver damage, especially if the maximum daily limit is surpassed.

Q: Does this medicine make you feel sleepy?

The caffeine component in this medication is a central nervous system stimulant. Regulatory documents note that the stimulating effect may cause side effects such as nervousness, irritability, sleeplessness (insomnia), and occasionally a rapid heartbeat. Drowsiness is not typically listed as a side effect for this specific combination.

Q: Can I take this medicine with alcohol?

Official product information includes a Liver Warning regarding alcohol use. Severe liver damage may occur if a person consumes three or more alcoholic drinks every day while using a product containing acetaminophen. The official warning is that users should limit or avoid alcoholic drinks.

Q: Is it safe to take this medication while pregnant or breastfeeding?

The regulatory documents state that a health professional should be asked or consulted before using this medication if pregnant or breastfeeding. Regarding breastfeeding, caffeine can pass into human milk, and official information notes the potential for effects such as irritability or poor sleep patterns in the infant.

Q: What should I do if I miss a dose?

This medication is typically taken as needed to treat symptoms, rather than on a regular schedule. The guidance for products taken as needed is generally to resume use when the next dose is required. Official administration instructions typically advise against taking a double dose to compensate for a missed one.

Q: Is this drug a controlled substance?

The controlled substance status depends on the exact formulation of the drug. A product containing only acetaminophen and caffeine is typically not listed as a controlled substance. However, some similar combination products that include ingredients like butalbital are classified as controlled substances by various government agencies.

Q: How long can I safely take this medicine for my symptoms?

A doctor should be consulted if pain worsens or lasts for more than 10 days, or if fever worsens or lasts for more than 3 days. Regulatory safety information advises against taking this product for longer than 3 consecutive days unless specifically instructed by a healthcare provider.

The storage and disposal of Ульгастран (Sucralfate) must strictly follow the requirements documented in official regulatory labeling to ensure product stability and safety.

Official Storage Requirements

Classification	Requirement	Constraint
Temperature	Store at controlled room temperature, typically 20-25 C (68-77 F).	Avoid freezing the oral suspension.
Container Integrity	Keep the medicine in its original container, tightly closed.	Protect from excess heat and moisture.
Child Safety	Keep out of the sight and reach of children.	Mandatory regulatory instruction.

Official Disposal Instructions

When disposing of unused or expired medicine, regulatory guidance advises against flushing the product down the toilet or pouring it into a drain. The preferred method is to utilize an official medicine take-back program. If this option is unavailable, the medicine should be mixed with an undesirable substance, placed into a sealed container, and discarded in the household trash. The shelf-life is typically 2 years.